F

Foghorn Therapeutics
D

FHTX

7.51000
USD
-0.39
(-4.94%)
Market Closed
Volume
3,518
EPS
-2
Div Yield
-
P/E
-4
Market Cap
417,504,414
OverviewSignalsIdeasNews
Related Instruments
    AAPL
    AAPL
    -3.130
    (-1.37%)
    235.000 USD
    A
    AMC
    -0.09500
    (-2.08%)
    4.48000 USD
    AMD
    AMD
    -3.910
    (-2.82%)
    137.700 USD
    B
    BB
    -0.04000
    (-1.66%)
    2.37000 USD
    G
    GME
    -0.790
    (-2.89%)
    26.560 USD
    MSFT
    MSFT
    -11.75
    (-2.75%)
    427.74 USD
    N
    NOK
    -0.03000
    (-0.67%)
    4.45500 USD
    NVDA
    NVDA
    -4.900
    (-3.34%)
    136.830 USD
    S
    SNDL
    0.00500
    (0.26%)
    1.95500 USD
    TSLA
    TSLA
    9.69
    (3.11%)
    338.16 USD
    More
News

Title: Foghorn Therapeutics

Sector: Healthcare
Industry: Biotechnology
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.